IOL Chemicals gains 7.8% on China Fenofibrate nod

What triggered the stock move

IOL Chemicals & Pharmaceuticals Ltd (IOL) climbed after China’s National Medical Products Administration (NMPA) approved the company’s Fenofibrate drug for the Chinese market. The approval enables IOL to export its Fenofibrate active pharmaceutical ingredient (API) to China, a regulatory step that widens the company’s export addressable market for this product.

On the market reaction, IOL Chemicals & Pharmaceuticals surged 7.76% to Rs 441.05 following the update on the NMPA clearance. The move underscores how closely investors track incremental regulatory access, especially for API exporters where approvals can open new geographies.

What the China approval covers

The regulatory clearance was communicated as approval by China’s NMPA for Fenofibrate manufactured by the company. The approval is positioned as a green light for export of Fenofibrate to China.

While the announcement focuses on Fenofibrate, the broader context is that the company has been working on regulatory access across major markets. Export expansion is described as a key growth driver, supported by regulatory approvals and registrations.

Another China milestone: Ibuprofen API approval

Separately, IOL has also disclosed that it received regulatory approval from China’s Center for Drug Evaluation (CDE) under the NMPA for its Ibuprofen API. The company stated this approval marks progress in entering the Chinese market for Ibuprofen.

The China approvals are noteworthy because they align with a stated focus on export expansion. They also sit alongside the company’s stated objective of reducing dependency on Ibuprofen by expanding its non-Ibuprofen product mix.

EU regulatory step: CEP for Clopidogrel Besilate

Beyond China, IOL Chemicals & Pharmaceuticals reported it received a Certificate of Suitability (CEP) for its API Clopidogrel Besilate. The certification was granted by the European Directorate for the Quality of Medicines & Health Care (EDQM) on February 23, 2026.

The company also noted it already holds a valid CEP for Clopidogrel Bisulphate. Together, these certifications increase the number of APIs where the company can point to CEP-backed regulatory readiness for Europe-linked markets.

Portfolio context: over 13 APIs

IOL describes itself as a manufacturer of APIs and specialty chemicals with a diversified portfolio of more than 13 APIs. The product list cited includes Metformin Hydrochloride, Clopidogrel Bisulfate Form II, Pantoprazole Sodium, and Losartan Potassium, among others.

The company was established in 1986 and operates as a generic pharmaceutical player focused on APIs, bulk drugs, and specialty chemicals across multiple therapeutic categories for domestic and international markets.

Capacity additions and operational updates cited

The company has commissioned a 10,800 MTPA Paracetamol unit at Barnala. It also expanded Clopidogrel capacity and highlighted progress in entering the China market.

In addition, Clopidogrel Bisulphate production capacity was increased from 180 MTPA to 240 MTPA at Unit-5, with an investment of INR 7.87 crore, which was stated to be internally funded.

FY25 financial snapshot mentioned

For FY25, IOLCPL’s revenue was stated to have declined 2.7% year-on-year to ₹2,087.55 crore. In the same period, it posted EBITDA of ₹224.6 crore with an EBITDA margin of 10.7%, and net profit (PAT) of ₹101 crore.

The coverage also highlighted key growth drivers as a diversified API portfolio, reduced dependency on Ibuprofen, and a ramp-up in non-Ibuprofen products such as Metformin, Paracetamol, and Clopidogrel.

Key facts at a glance

Why the approvals matter for an API exporter

For API companies, approvals from regulators such as China’s NMPA and Europe’s EDQM typically determine where products can be supplied and how quickly new business can be pursued. The Fenofibrate approval adds one more product that can be exported to China, while the Ibuprofen approval provides a separate China entry point in a high-volume API.

The EU CEP for Clopidogrel Besilate strengthens the company’s compliance profile for regulated-market customers and complements the existing CEP for Clopidogrel Bisulphate. These developments are also consistent with the stated goal of expanding non-Ibuprofen products.

What to watch next

The company’s recent updates cluster around regulatory clearances, capacity additions, and product diversification. Future disclosures that investors typically track in such cases include timelines for commercial shipments, customer onboarding in newly accessible markets, and any incremental capacity utilisation data tied to newly approved products.

For now, the immediate confirmed development is the NMPA approval enabling Fenofibrate exports to China, alongside the previously cited China approval for Ibuprofen API and the February 2026 CEP milestone for Clopidogrel Besilate.